cbdMD (YCBD) Capital Expenditures Growth (1y) (2017 - 2025)
cbdMD (YCBD) Capital Expenditures Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.25% |
| Sep 30, 2025 | -71.96% |
| Mar 31, 2025 | 435.63% |
| Dec 31, 2024 | -10.97% |
| Sep 30, 2024 | -91.68% |
| Mar 31, 2024 | 95.49% |
| Dec 31, 2023 | 4.10% |
| Sep 30, 2023 | -46.93% |
| Jun 30, 2023 | 15.79% |
| Mar 31, 2023 | -171.72% |
| Dec 31, 2022 | -23.23% |
| Sep 30, 2022 | 643.93% |
| Jun 30, 2022 | 3.99% |
| Mar 31, 2022 | 7.14% |
| Dec 31, 2021 | 147.64% |
| Sep 30, 2021 | 105.73% |
| Jun 30, 2021 | 53.48% |
| Mar 31, 2021 | -89.26% |
| Dec 31, 2020 | -83.21% |
| Sep 30, 2020 | -163.35% |